{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T08:05:23Z","timestamp":1791446723998,"version":"4.3.3"},"reference-count":63,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,10,4]],"date-time":"2024-10-04T00:00:00Z","timestamp":1728000000000},"content-version":"vor","delay-in-days":369,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001711","name":"Schweizerischer Nationalfonds zur Forderung der wissenschaftlichen Forschung","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001711","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Therapy"],"published-print":{"date-parts":[[2023,10]]},"DOI":"10.1016\/j.ymthe.2023.08.018","type":"journal-article","created":{"date-parts":[[2023,8,28]],"date-time":"2023-08-28T01:57:40Z","timestamp":1693187860000},"page":"2914-2928","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":25,"title":["FAP-retargeted Ad5 enables in\u00a0vivo gene delivery to stromal cells in the tumor microenvironment"],"prefix":"10.1016","volume":"31","author":[{"given":"K. Patricia","family":"Hartmann","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Merel","family":"van Gogh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick C.","family":"Freitag","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florian","family":"Kast","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriela","family":"Nagy-Davidescu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lubor","family":"Borsig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Pl\u00fcckthun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ymthe.2023.08.018_bib1","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1126\/science.aaa8172","article-title":"The future of immune checkpoint therapy","volume":"348","author":"Sharma","year":"2015","journal-title":"Science"},{"key":"10.1016\/j.ymthe.2023.08.018_bib2","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1038\/s41416-018-0328-y","article-title":"Cytokines in clinical cancer immunotherapy","volume":"120","author":"Berraondo","year":"2019","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.ymthe.2023.08.018_bib3","doi-asserted-by":"crossref","DOI":"10.1002\/jgm.3108","article-title":"Clinical translation of gene medicine","volume":"21","author":"Wang","year":"2019","journal-title":"J.\u00a0Gene Med."},{"key":"10.1016\/j.ymthe.2023.08.018_bib4","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1099\/vir.0.003087-0","article-title":"Adenoviruses: update on structure and function","volume":"90","author":"Russell","year":"2009","journal-title":"J.\u00a0Gen. Virol."},{"key":"10.1016\/j.ymthe.2023.08.018_bib5","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1038\/s41392-021-00487-6","article-title":"Viral vector platforms within the gene therapy landscape","volume":"6","author":"Bulcha","year":"2021","journal-title":"Signal Transduct. Target. Ther."},{"key":"10.1016\/j.ymthe.2023.08.018_bib6","doi-asserted-by":"crossref","first-page":"5483","DOI":"10.1073\/pnas.0711757105","article-title":"Adenovirus serotype 5 hexon is critical for virus infection of hepatocytes in\u00a0vivo","volume":"105","author":"Kalyuzhniy","year":"2008","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.ymthe.2023.08.018_bib7","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1016\/j.cell.2008.01.016","article-title":"Adenovirus serotype 5 hexon mediates liver gene transfer","volume":"132","author":"Waddington","year":"2008","journal-title":"Cell"},{"key":"10.1016\/j.ymthe.2023.08.018_bib8","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1038\/gt.2011.87","article-title":"Coagulation factor X mediates adenovirus type 5 liver gene transfer in non-human primates (Microcebus murinus)","volume":"19","author":"Alba","year":"2012","journal-title":"Gene Ther."},{"key":"10.1016\/j.ymthe.2023.08.018_bib9","doi-asserted-by":"crossref","first-page":"3352","DOI":"10.1073\/pnas.94.7.3352","article-title":"HCAR and MCAR: the human and mouse cellular receptors for subgroup C adenoviruses and group B coxsackieviruses","volume":"94","author":"Tomko","year":"1997","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.ymthe.2023.08.018_bib10","doi-asserted-by":"crossref","first-page":"1320","DOI":"10.1126\/science.275.5304.1320","article-title":"Isolation of a common receptor for Coxsackie B viruses and adenoviruses 2 and 5","volume":"275","author":"Bergelson","year":"1997","journal-title":"Science"},{"key":"10.1016\/j.ymthe.2023.08.018_bib11","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/0092-8674(93)90231-E","article-title":"Integrins alpha v beta 3 and alpha v beta 5 promote adenovirus internalization but not virus attachment","volume":"73","author":"Wickham","year":"1993","journal-title":"Cell"},{"key":"10.1016\/j.ymthe.2023.08.018_bib12","doi-asserted-by":"crossref","first-page":"S152","DOI":"10.1002\/jgm.553","article-title":"Adenovirus endocytosis","volume":"6","author":"Meier","year":"2004","journal-title":"J.\u00a0Gene Med."},{"key":"10.1016\/j.ymthe.2023.08.018_bib13","doi-asserted-by":"crossref","first-page":"6839","DOI":"10.1128\/jvi.70.10.6839-6846.1996","article-title":"Generation of recombinant adenovirus vectors with modified fibers for altering viral tropism","volume":"70","author":"Krasnykh","year":"1996","journal-title":"J.\u00a0Virol."},{"key":"10.1016\/j.ymthe.2023.08.018_bib14","doi-asserted-by":"crossref","first-page":"1574","DOI":"10.1038\/nbt1196-1574","article-title":"Targeted gene delivery by tropism-modified adenoviral vectors","volume":"14","author":"Douglas","year":"1996","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.ymthe.2023.08.018_bib15","first-page":"660","article-title":"Addition of a short peptide ligand to the adenovirus fiber protein","volume":"2","author":"Michael","year":"1995","journal-title":"Gene Ther."},{"key":"10.1016\/j.ymthe.2023.08.018_bib16","doi-asserted-by":"crossref","first-page":"1276","DOI":"10.1038\/mt.2008.86","article-title":"Modification of adenoviral vectors with polyethylene glycol modulates in\u00a0vivo tissue tropism and gene expression","volume":"16","author":"Hofherr","year":"2008","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymthe.2023.08.018_bib17","doi-asserted-by":"crossref","first-page":"1918","DOI":"10.1002\/1873-3468.13731","article-title":"Retargeting adenoviruses for therapeutic applications and vaccines","volume":"594","author":"Barry","year":"2020","journal-title":"FEBS Lett."},{"key":"10.1016\/j.ymthe.2023.08.018_bib18","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1038\/s41467-017-02707-6","article-title":"Adenoviral vector with shield and adapter increases tumor specificity and escapes liver and immune control","volume":"9","author":"Schmid","year":"2018","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ymthe.2023.08.018_bib19","doi-asserted-by":"crossref","first-page":"7179","DOI":"10.4049\/jimmunol.174.11.7179","article-title":"Neutralizing antibodies to adenovirus serotype 5 vaccine vectors are directed primarily against the adenovirus hexon protein","volume":"174","author":"Sumida","year":"2005","journal-title":"J.\u00a0Immunol."},{"key":"10.1016\/j.ymthe.2023.08.018_bib20","doi-asserted-by":"crossref","first-page":"5203","DOI":"10.1016\/j.vaccine.2011.05.025","article-title":"International seroepidemiology of adenovirus serotypes 5, 26, 35, and 48 in pediatric and adult populations","volume":"29","author":"Barouch","year":"2011","journal-title":"Vaccine"},{"key":"10.1016\/j.ymthe.2023.08.018_bib21","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1016\/j.jmb.2010.10.040","article-title":"Her2-specific multivalent adapters confer designed tropism to adenovirus for gene targeting","volume":"405","author":"Dreier","year":"2011","journal-title":"J.\u00a0Mol. Biol."},{"key":"10.1016\/j.ymthe.2023.08.018_bib22","doi-asserted-by":"crossref","first-page":"E869","DOI":"10.1073\/pnas.1213653110","article-title":"Development of a generic adenovirus delivery system based on structure-guided design of bispecific trimeric DARPin adapters","volume":"110","author":"Dreier","year":"2013","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.ymthe.2023.08.018_bib23","doi-asserted-by":"crossref","first-page":"1595","DOI":"10.1021\/acs.bioconjchem.2c00346","article-title":"Modular adapters utilizing binders of different molecular types expand cell-targeting options for adenovirus gene delivery","volume":"33","author":"Freitag","year":"2022","journal-title":"Bioconjug. Chem."},{"key":"10.1016\/j.ymthe.2023.08.018_bib24","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1038\/nrc.2016.73","article-title":"The biology and function of fibroblasts in cancer","volume":"16","author":"Kalluri","year":"2016","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.ymthe.2023.08.018_bib25","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1038\/s41416-019-0705-1","article-title":"The life cycle of cancer-associated fibroblasts within the tumour stroma and its importance in disease outcome","volume":"122","author":"D'Arcangelo","year":"2020","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.ymthe.2023.08.018_bib26","first-page":"6406","article-title":"Differential expression of cell surface antigens and glial fibrillary acidic protein in human astrocytoma subsets","volume":"46","author":"Rettig","year":"1986","journal-title":"Cancer Res."},{"key":"10.1016\/j.ymthe.2023.08.018_bib27","doi-asserted-by":"crossref","first-page":"3110","DOI":"10.1073\/pnas.85.9.3110","article-title":"Cell-surface glycoproteins of human sarcomas: differential expression in normal and malignant tissues and cultured cells","volume":"85","author":"Rettig","year":"1988","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.ymthe.2023.08.018_bib28","doi-asserted-by":"crossref","first-page":"7235","DOI":"10.1073\/pnas.87.18.7235","article-title":"Cell surface glycoprotein of reactive stromal fibroblasts as a potential antibody target in human epithelial cancers","volume":"87","author":"Garin-Chesa","year":"1990","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.ymthe.2023.08.018_bib29","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1200\/JCO.1994.12.6.1193","article-title":"Antibody targeting in metastatic colon cancer: a phase I study of monoclonal antibody F19 against a cell-surface protein of reactive tumor stromal fibroblasts","volume":"12","author":"Welt","year":"1994","journal-title":"J.\u00a0Clin. Oncol."},{"key":"10.1016\/j.ymthe.2023.08.018_bib30","first-page":"1639","article-title":"A Phase I dose-escalation study of sibrotuzumab in patients with advanced or metastatic fibroblast activation protein-positive cancer","volume":"9","author":"Scott","year":"2003","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ymthe.2023.08.018_bib31","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1021\/ml300410d","article-title":"Selective inhibitors of Fibroblast Activation Protein (FAP) with a (4-quinolinoyl)-glycyl-2-cyanopyrrolidine scaffold","volume":"4","author":"Jansen","year":"2013","journal-title":"ACS Med. Chem. Lett."},{"key":"10.1016\/j.ymthe.2023.08.018_bib32","doi-asserted-by":"crossref","first-page":"801","DOI":"10.2967\/jnumed.119.227967","article-title":"(68)Ga-FAPI PET\/CT: Tracer uptake in 28 different kinds of cancer","volume":"60","author":"Kratochwil","year":"2019","journal-title":"J. Nucl. Med."},{"key":"10.1016\/j.ymthe.2023.08.018_bib33","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2101852118","article-title":"An ultra-high-affinity small organic ligand of fibroblast activation protein for tumor-targeting applications","volume":"118","author":"Millul","year":"2021","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.ymthe.2023.08.018_bib34","doi-asserted-by":"crossref","first-page":"3613","DOI":"10.1172\/JCI38988","article-title":"Targeting fibroblast activation protein inhibits tumor stromagenesis and growth in mice","volume":"119","author":"Santos","year":"2009","journal-title":"J.\u00a0Clin. Invest."},{"key":"10.1016\/j.ymthe.2023.08.018_bib35","doi-asserted-by":"crossref","first-page":"5471","DOI":"10.1158\/0008-5472.CAN-04-0447","article-title":"PT-100, a small molecule dipeptidyl peptidase inhibitor, has potent antitumor effects and augments antibody-mediated cytotoxicity via a novel immune mechanism","volume":"64","author":"Adams","year":"2004","journal-title":"Cancer Res."},{"key":"10.1016\/j.ymthe.2023.08.018_bib36","doi-asserted-by":"crossref","first-page":"1320","DOI":"10.1093\/jnci\/djs336","article-title":"Targeting carcinoma-associated fibroblasts within the tumor stroma with a fibroblast activation protein-activated prodrug","volume":"104","author":"Brennen","year":"2012","journal-title":"J.\u00a0Natl. Cancer Inst."},{"key":"10.1016\/j.ymthe.2023.08.018_bib37","doi-asserted-by":"crossref","first-page":"5320","DOI":"10.1021\/acs.jmedchem.6b01755","article-title":"Fibroblast Activation Protein alpha activated tripeptide bufadienolide antitumor prodrug with reduced cardiotoxicity","volume":"60","author":"Deng","year":"2017","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ymthe.2023.08.018_bib38","doi-asserted-by":"crossref","first-page":"1611","DOI":"10.1038\/mt.2013.110","article-title":"Antitumor effects of chimeric receptor engineered human T\u00a0cells directed to tumor stroma","volume":"21","author":"Kakarla","year":"2013","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymthe.2023.08.018_bib39","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1186\/1479-5876-11-187","article-title":"Treatment of malignant pleural mesothelioma by fibroblast activation protein-specific re-directed T\u00a0cells","volume":"11","author":"Schuberth","year":"2013","journal-title":"J.\u00a0Transl. Med."},{"key":"10.1016\/j.ymthe.2023.08.018_bib40","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1158\/2326-6066.CIR-13-0027","article-title":"Targeting fibroblast activation protein in tumor stroma with chimeric antigen receptor T\u00a0cells can inhibit tumor growth and augment host immunity without severe toxicity","volume":"2","author":"Wang","year":"2014","journal-title":"Cancer Immunol. Res."},{"key":"10.1016\/j.ymthe.2023.08.018_bib41","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aav5989","article-title":"Tumor-targeted 4-1BB agonists for combination with T\u00a0cell bispecific antibodies as off-the-shelf therapy","volume":"11","author":"Claus","year":"2019","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.ymthe.2023.08.018_bib42","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2021.648187","article-title":"Fibroblast Activation Protein-alpha as a target in the bench-to-bedside diagnosis and treatment of tumors: A narrative review","volume":"11","author":"Xin","year":"2021","journal-title":"Front. Oncol."},{"key":"10.1016\/j.ymthe.2023.08.018_bib43","doi-asserted-by":"crossref","first-page":"19441","DOI":"10.1074\/jbc.C500092200","article-title":"Structural and kinetic analysis of the substrate specificity of human fibroblast activation protein alpha","volume":"280","author":"Aertgeerts","year":"2005","journal-title":"J.\u00a0Biol. Chem."},{"key":"10.1016\/j.ymthe.2023.08.018_bib44","doi-asserted-by":"crossref","first-page":"4937","DOI":"10.1073\/pnas.94.10.4937","article-title":"In\u00a0vitro selection and evolution of functional proteins by using ribosome display","volume":"94","author":"Hanes","year":"1997","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.ymthe.2023.08.018_bib45","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1016\/S0022-2836(03)00896-9","article-title":"Designing repeat proteins: well-expressed, soluble and stable proteins from combinatorial libraries of consensus ankyrin repeat proteins","volume":"332","author":"Binz","year":"2003","journal-title":"J.\u00a0Mol. Biol."},{"key":"10.1016\/j.ymthe.2023.08.018_bib46","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1038\/301527a0","article-title":"A severe combined immunodeficiency mutation in the mouse","volume":"301","author":"Bosma","year":"1983","journal-title":"Nature"},{"key":"10.1016\/j.ymthe.2023.08.018_bib47","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1038\/278451a0","article-title":"The beige mutation in the mouse selectively impairs natural killer cell function","volume":"278","author":"Roder","year":"1979","journal-title":"Nature"},{"key":"10.1016\/j.ymthe.2023.08.018_bib48","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2021.103269","article-title":"The prognostic impact of the tumour stroma fraction: A machine learning-based analysis in 16 human solid tumour types","volume":"65","author":"Micke","year":"2021","journal-title":"EBioMedicine"},{"key":"10.1016\/j.ymthe.2023.08.018_bib49","doi-asserted-by":"crossref","first-page":"987","DOI":"10.3892\/mco.2015.609","article-title":"Superior antitumor activity of trastuzumab combined with capecitabine plus oxaliplatin in a human epidermal growth factor receptor 2-positive human gastric cancer xenograft model","volume":"3","author":"Harada","year":"2015","journal-title":"Mol. Clin. Oncol."},{"key":"10.1016\/j.ymthe.2023.08.018_bib50","doi-asserted-by":"crossref","first-page":"11705","DOI":"10.1128\/JVI.01320-08","article-title":"Clearance of adenovirus by Kupffer cells is mediated by scavenger receptors, natural antibodies, and complement","volume":"82","author":"Xu","year":"2008","journal-title":"J.\u00a0Virol."},{"key":"10.1016\/j.ymthe.2023.08.018_bib51","doi-asserted-by":"crossref","first-page":"2293","DOI":"10.1128\/JVI.05760-11","article-title":"Identification of adenovirus serotype 5 hexon regions that interact with scavenger receptors","volume":"86","author":"Khare","year":"2012","journal-title":"J.\u00a0Virol."},{"key":"10.1016\/j.ymthe.2023.08.018_bib52","doi-asserted-by":"crossref","first-page":"2605","DOI":"10.1099\/0022-1317-81-11-2605","article-title":"Blood clearance rates of adenovirus type 5 in mice","volume":"81","author":"Alemany","year":"2000","journal-title":"J.\u00a0Gen. Virol."},{"key":"10.1016\/j.ymthe.2023.08.018_bib53","doi-asserted-by":"crossref","first-page":"8355","DOI":"10.3390\/ijms22158355","article-title":"Development of a bispecific antibody-based platform for retargeting of capsid modified AAV vectors","volume":"22","author":"Kuklik","year":"2021","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ymthe.2023.08.018_bib54","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2017925118","article-title":"The SHREAD gene therapy platform for paracrine delivery improves tumor localization and intratumoral effects of a clinical antibody","volume":"118","author":"Smith","year":"2021","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.ymthe.2023.08.018_bib55","doi-asserted-by":"crossref","first-page":"51","DOI":"10.2174\/157488408783329931","article-title":"Clinical pharmacology of trastuzumab","volume":"3","author":"Lev\u00eaque","year":"2008","journal-title":"Curr. Clin. Pharmacol."},{"key":"10.1016\/j.ymthe.2023.08.018_bib56","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1124\/dmd.119.087809","article-title":"Effect of size on solid tumor disposition of protein therapeutics","volume":"47","author":"Li","year":"2019","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.ymthe.2023.08.018_bib57","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1016\/j.omtm.2021.01.002","article-title":"iMATCH: an integrated modular assembly system for therapeutic combination high-capacity adenovirus gene therapy","volume":"20","author":"Br\u00fccher","year":"2021","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"10.1016\/j.ymthe.2023.08.018_bib58","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.1002\/ibd.21446","article-title":"Fibroblast activation protein expression in Crohn's disease strictures","volume":"17","author":"Rovedatti","year":"2011","journal-title":"Inflamm. Bowel Dis."},{"key":"10.1016\/j.ymthe.2023.08.018_bib59","doi-asserted-by":"crossref","first-page":"R171","DOI":"10.1186\/ar2080","article-title":"Fibroblast activation protein is expressed by rheumatoid myofibroblast-like synoviocytes","volume":"8","author":"Bauer","year":"2006","journal-title":"Arthritis Res. Ther."},{"key":"10.1016\/j.ymthe.2023.08.018_bib60","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1038\/s41586-019-1263-7","article-title":"Distinct fibroblast subsets drive inflammation and damage in arthritis","volume":"570","author":"Croft","year":"2019","journal-title":"Nature"},{"key":"10.1016\/j.ymthe.2023.08.018_bib61","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1016\/j.humpath.2005.11.020","article-title":"Fibroblast activation protein: a serine protease expressed at the remodeling interface in idiopathic pulmonary fibrosis","volume":"37","author":"Acharya","year":"2006","journal-title":"Hum. Pathol."},{"key":"10.1016\/j.ymthe.2023.08.018_bib62","doi-asserted-by":"crossref","first-page":"1768","DOI":"10.1002\/hep.510290631","article-title":"Fibroblast activation protein: a cell surface dipeptidyl peptidase and gelatinase expressed by stellate cells at the tissue remodelling interface in human cirrhosis","volume":"29","author":"Levy","year":"1999","journal-title":"Hepatology"},{"key":"10.1016\/j.ymthe.2023.08.018_bib63","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1038\/nbt962","article-title":"High-affinity binders selected from designed ankyrin repeat protein libraries","volume":"22","author":"Binz","year":"2004","journal-title":"Nat. Biotechnol."}],"container-title":["Molecular Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525001623004513?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525001623004513?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T18:10:02Z","timestamp":1761502202000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1525001623004513"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10]]},"references-count":63,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2023,10]]}},"alternative-id":["S1525001623004513"],"URL":"https:\/\/doi.org\/10.1016\/j.ymthe.2023.08.018","relation":{},"ISSN":["1525-0016"],"issn-type":[{"value":"1525-0016","type":"print"}],"subject":[],"published":{"date-parts":[[2023,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"FAP-retargeted Ad5 enables in\u00a0vivo gene delivery to stromal cells in the tumor microenvironment","name":"articletitle","label":"Article Title"},{"value":"Molecular Therapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ymthe.2023.08.018","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The American Society of Gene and Cell Therapy.","name":"copyright","label":"Copyright"}]}}